Minnesota

For Minnesota, generic/biosimilar trigger is 50% over the previous 12 months; statute is S.F. 2995, verified against its source on 2026-08-14.

State: Minnesota verified
Generic/biosimilar trigger: 50% over the previous 12 months verified
Statute: S.F. 2995 verified

Sourcegoodwinlaw.com

Verified2026-08-14

Review by2027-02-10

DatasetState drug price transparency reporting thresholds, triggers, and penalties for pharmaceutical manufacturers

What the source says

Minnesota : <https://www.revisor.mn.gov/bills/text.php?version=latest&number=SF2995&session=ls93&session_year=&session_number=0> S.F. 2995 amends the state’s Prescription Drug Price Transparency Act to include some technical fixes and clarifications, such as explicitly including “biosimilars” along with generic drugs in the provision that triggers reporting when there is a WAC increase of at least 50% over the previous 12 months.

— goodwinlaw.com, retrieved 2026-08-14

Source

goodwinlaw.comhttps://www.goodwinlaw.com/en/insights/publications/2025/06/alerts-lifesciences-state-drug-transparency-laws

Last verified against source: 2026-08-14. Due for re-check by 2027-02-10. This page as Markdown · OKF bundle · full dataset as JSON.